BridgeBio Pharma grants 66,810 RSUs to 30 new employees
BridgeBio Pharma, Inc. approved equity grants of 66,810 restricted stock units to 30 new employees as an employment inducement under Nasdaq Listing Rule 5635(c)(4). The awards, granted on June 18, 2026, will vest starting May 16, 2027, subject to continued employment.
*this image is generated using AI for illustrative purposes only.
BridgeBio Pharma, Inc. granted 66,810 restricted stock units to 30 new employees as an inducement for entering into employment with the company. The compensation committee of BridgeBio’s board of directors approved the equity grants on June 18, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4). The awards were issued pursuant to the terms of the company’s equity incentive plan, which was originally adopted in November 2019 and subsequently amended and restated on February 10, 2023, and December 13, 2023.
Vesting Schedule
The vesting of the restricted stock units is structured to encourage long-term retention. One-fourth of the shares underlying each employee’s restricted stock units will vest on May 16, 2027. The remaining shares will vest on a quarterly basis thereafter, with one-twelfth of the remaining shares vesting each quarter. All vesting is contingent upon the employee’s continued employment with BridgeBio or one of its subsidiaries on the applicable vesting dates.
Grant Details
| Grant Detail | Information |
|---|---|
| Total Shares Granted | 66,810 |
| Number of Employees | 30 |
| Grant Date | June 18, 2026 |
| Initial Vesting Date | May 16, 2027 |
| Governing Rule | Nasdaq Listing Rule 5635(c)(4) |
How will the addition of 30 new employees impact BridgeBio's operational capacity and pipeline development?
What specific roles or expertise do these new hires bring to the company?
How does this hiring trend align with BridgeBio's strategic goals for 2026 and beyond?
17
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
